Calgary-based privately held licensed dealer and active pharmaceutical ingredient (API) manufacturer founded in 2019, focused exclusively on manufacturing psychedelic and neuroplastogen APIs. Its purpose-built 17,000-sq-ft facility supports process R&D and large-scale synthesis, and its Health Canada dealer's licence authorizes handling of LSD, MDMA, psilocybin, psilocin, DMT, 2C-B and mescaline. It has exported APIs internationally and donated substances through Canada's Special Access Program.
Psygen News 6 articles
- Danny Motyka Manufactures Psychedelics for the Masses – Podcast Episode #5
- Psygen Announces That Psilocybin from Its Patent-Pending Process Has Been Used in Human Trial
- Psygen Industries Ltd. and Larose Ventures Ltd. Announce Reverse Takeover Transaction
- NeonMind Purchases Synthetic Psilocybin from Psygen Labs
- Entheon Biomedical Announces DMT Drug Supply Agreement with Psygen Labs Inc. Completion of Initial DMT Research Drug Batch
- Better Plant Sciences Subsidiary NeonMind Signs Psilocybin Supply Agreement for Clinical Trials